The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Name:	us-gaap_UnrealizedGainLossOnDerivatives
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012 Derivative Liabilities	Sep. 30, 2011 Derivative Liabilities	Sep. 30, 2012 Fair Value, Inputs, Level 3 Warrants	Sep. 30, 2011 Fair Value, Inputs, Level 3 Warrants	Sep. 30, 2012 PharmAthene	Sep. 30, 2011 PharmAthene	Dec. 30, 2011 PharmAthene	Dec. 31, 2010 PharmAthene
Fair Value Measurements [Line Items]
Warrants to purchase common stock					2,899,991	2,899,991
Unrealized gains on the Change in market value of derivative instruments	$ 508,971	$ 2,898,869	$ 341,118	$ 6,075,555			$ (341,118)	$ (6,075,555)
Closing stock price, per share									$ 1.18	$ 1.76	$ 1.27	$ 4.23